Feligen Rcp

Target species Cats. Indications for use, specifying the target species The vaccine is intended for the active immunisation of healthy cats of minimum 9 weeks of age against: - feline calicivirosis and feline viral rhinotracheitis to reduce clinical signs and viral excretion; - feline panleucopenia to prevent leucopenia and to reduce clinical signs. Onset of immunity is established four weeks after vaccination for calici virus and rhinotracheitis and three weeks for panleucopenia virus. This immunity lasts for 12 months. Contraindications None. Special warnings for each target species High level of maternal antibodies can interfere with the response to vaccination. Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination. Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals i. Special precautions for use in animals Vaccinate only healthy animals. ii. Special precautions for the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Some transient post-vaccinal digestive disturbances were very commonly observed in safety studies. A slight and transient oedema which disappears spontaneously within 2 days was commonly observed during the days following vaccination in safety studies. Some transient and self-resolving post-vaccinal signs such as a slight hyperthermia and lethargy were commonly observed in safety studies. Hypersensitivity reactions (e.g. emesis, diarrhoea, dyspnoea, allergic oedema) have been reported in very rare cases from spontaneous reports. In case of such an allergic or anaphylactic reaction, appropriate symptomatic treatment should be administered. As reported in the literature, after the use of any vaccine containing a Feline Calicivirus component, febrile limping syndrome reactions may occur very rarely in kittens. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 4.7 Use during pregnancy, lactation or lay Do not use during pregnancy and lactation. 4.8 Interaction with other medicinal products and other forms of interaction Safety and/or efficacy data are available which demonstrate that this vaccine can be mixed with Leucogen. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.